Torbay Hospital
Welcome,         Profile    Billing    Logout  
 14 Trials 
36 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Turner, Deborah
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting
2/3
148
Europe
Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
University College, London, Janssen-Cilag Ltd.
Waldenstrom Macroglobulinemia
03/30
03/30
Person, Contact
PATCH, NCT00303784 / 2005-001030-33: Prostate Adenocarcinoma TransCutaneous Hormones

Recruiting
3
2200
Europe
Goserelin, Zoladex, Estradiol, FemSeven
University College, London, Medical Research Council
Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
08/21
08/21
UKALL14, NCT01085617 / 2009-012717-22: Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Active, not recruiting
3
1033
NA
palifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, imatinib mesylate, melphalan, mercaptopurine, methotrexate, nelarabine, pegaspargase, vincristine sulfate, allogeneic hematopoietic stem cell transplantation, total-body irradiation
University College, London
Leukemia, Mucositis, Oral Complications
12/24
12/25
STAMPEDE, NCT00268476: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Active, not recruiting
2/3
11992
Europe
Celecoxib, Celebrex, Docetaxel, Taxotere, Prednisolone, Prednisone, ADT, Androgen Deprivation Therapy, Zoledronic Acid, Zometa, Abiraterone, Zytiga, Radiotherapy to the prostate, RT, Enzalutamide, Xtandi, Metformin, Metformin Hydrochloride, Transdermal Oestradiol, Progynova TS
Medical Research Council
Prostate Cancer
03/26
12/30
NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

Recruiting
2
75
US, Europe
tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis
Baylor College of Medicine
Bladder Cancer
07/10
 
NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting
2
64
US
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.
HER2-negative Breast Cancer
10/23
10/23
PRISM, NCT03658525: Prostate Radiotherapy Integrated With Simultaneous MRI (The Study)

Recruiting
N/A
30
Europe
MR LINAC
Royal Marsden NHS Foundation Trust
Prostate Cancer
08/20
08/23
NCT06032663: Use of PET-MR in Head and Neck Cancer Patients - Diagnostic and Therapeutic Applications

Recruiting
N/A
10
Europe
PET-MRI
Sheffield Teaching Hospitals NHS Foundation Trust
Head and Neck Cancer
10/24
10/25
NCT01840293: Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting
N/A
1780
Europe
Cancer Trials Ireland
Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
12/29
01/38
Felmeden, Dirk
SENIOR-RITA, NCT03052036: The British Heart Foundation Trial

Active, not recruiting
N/A
1518
Europe
Coronary Angiography, Coronary revascularisation, Optimal Medical Therapy
Newcastle-upon-Tyne Hospitals NHS Trust, British Heart Foundation, Newcastle University
NSTEMI - Non-ST Segment Elevation MI
03/24
06/29
Eve, Heather
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
Smith, Jamie
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
Bliss, Peter
INTERLACE, NCT01566240 / 2011-001300-35: Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

Active, not recruiting
3
500
Europe, RoW
Paclitaxel, Carboplatin, Radiotherapy, Cisplatin
University College, London, Cancer Research UK
Cervical Cancer
02/26
12/26
Lydon, Anna
RAMPART, NCT03288532 / 2017-002329-39: Renal Adjuvant MultiPle Arm Randomised Trial

Hourglass Oct 2023 - Dec 2023 : From RAMPART trial with or without in combination with tremelimumab
Recruiting
3
1750
Europe
Durvalumab, Tremelimumab
University College, London, AstraZeneca, Kidney Cancer UK, Cancer Research UK
Renal Cell Carcinoma
07/24
12/34
Roberts, Fiona
NCT03985202: Structured Exercise Programme and Abdominal Aortic Aneurysm Surgery

Recruiting
N/A
60
Europe
Structured exercise programme, Qualitiative interviews and questionnaires
Torbay and South Devon NHS Foundation Trust
Abdominal Aortic Aneurysm
10/23
10/23
NCT06756464: ROHKEA: Virtual Reality Therapy 12-week Programme for Chronic Pain

Not yet recruiting
N/A
6
Europe
ROHKEA: Virtual Reality Therapy
Torbay and South Devon NHS Foundation Trust, Torbay Hospital
Musculoskeletal
07/25
07/25
Heartin, Earnest
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
Cole, Naomi
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
Chambers, Jonathan
ASCOT, NCT04483960: Australasian COVID-19 Trial () ADAptive Platform Trial

Active, not recruiting
3
2200
RoW
(Arm Closed) Nafamostat Mesilate, Nafabelltan, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin, (Arm Closed) Tinzaparin, (Arm Never Opened) Hyperimmune globulin, Nirmatrelvir-Ritonavir, Paxlovid, Remdesivir, Veklury
University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Aotearoa Clinical Trials, Australian and New Zealand Intensive Care Research Centre
SARS-CoV-2 Infection (COVID-19)
07/25
12/25
CompARE, NCT04116047 / 2014-003389-26: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Active, not recruiting
3
785
Europe
Cisplatin, CDDP, Platinol, Durvalumab, MEDI-4736, Imfinzi, Radiotherapy
University of Birmingham, AstraZeneca, Cancer Trials Ireland
Oropharyngeal Cancer
12/26
12/30
Haworth, Peter
ORBITA-2, NCT03742050: A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina

Completed
N/A
439
Europe
Percutaneous coronary intervention, Coronary angioplasty
Imperial College London, Basildon and Thurrock Hospitals NHS FoundationTrust
Stable Angina
09/23
09/23
ORBITA-MOON, NCT06400290: Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina

Recruiting
N/A
60
Europe
Percutaneous coronary intervention (PCI), Symptom assessment during experimentally induced ischaemia
Imperial College London, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Mid and South Essex NHS Foundation Trust, Imperial College Healthcare NHS Trust, St George's Healthcare NHS Trust, Royal Free Hospital NHS Foundation Trust
Stable Angina, Multivessel Coronary Artery Disease
01/27
04/27
ORBITA-FIRE, NCT05459051: Finding the Invasive Haemodynamic Threshold for Symptom Relief in Stable Angina

Recruiting
N/A
58
Europe
Rest-angina physiological assessment, Exercise-angina physiological assessment
Imperial College London, Royal Free Hospital NHS Foundation Trust, Mid and South Essex NHS Foundation Trust, St George's University Hospitals NHS Foundation Trust, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Portsmouth Hospitals NHS Trust
Stable Angina
04/25
04/25
EASY-AS, NCT04204915: The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

Recruiting
N/A
2844
Europe, RoW
Aortic valve replacement
University of Leicester, University of Auckland, New Zealand, University Hospitals, Leicester, The University of Western Australia
Aortic Stenosis
04/31
04/31
Medley, Louise
CUP-COMP, NCT04750109: Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers

Completed
N/A
117
Europe
The Christie NHS Foundation Trust, Hoffmann-La Roche, Concr, Durham University
Cancer of Unknown Primary Site
06/24
06/24
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Sheikh, Usman
EASY-AS, NCT04204915: The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

Recruiting
N/A
2844
Europe, RoW
Aortic valve replacement
University of Leicester, University of Auckland, New Zealand, University Hospitals, Leicester, The University of Western Australia
Aortic Stenosis
04/31
04/31
Ibrahim, Mokhtar
PROTECT-HF, NCT05815745: "Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment"

Recruiting
N/A
2600
Europe
Pacemaker - Physiological pacing, Pacemaker - Right Ventricular pacing
Imperial College London, British Heart Foundation
Bradycardia, Pacing, Right Ventricular Pacing, His Bundle Pacing, Left Bundle Branch Area Pacing
12/29
12/29
Salbach, Peter
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
Thomas, Charlotte
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
Lo, Nangi
CORRECT-MRD I, NCT06398743: First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

Recruiting
N/A
400
Europe, RoW
MRD
Exact Sciences Corporation, Labcorp Corporation of America Holdings, Inc
Colorectal Cancer
06/29
06/29
Anning, Louise Dr
VitalBE, NCT03696290 / 2018-001590-24: Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Recruiting
2
77
Europe
Aztreonam lysine, Cayston, Placebo, Lactose monohydrate
University of Dundee, Gilead Sciences
Bronchiectasis Adult
09/25
09/25
Cross, Phillipa Newton
NCT06756464: ROHKEA: Virtual Reality Therapy 12-week Programme for Chronic Pain

Not yet recruiting
N/A
6
Europe
ROHKEA: Virtual Reality Therapy
Torbay and South Devon NHS Foundation Trust, Torbay Hospital
Musculoskeletal
07/25
07/25
Newton-Cross, Phillipa
NCT06756464: ROHKEA: Virtual Reality Therapy 12-week Programme for Chronic Pain

Not yet recruiting
N/A
6
Europe
ROHKEA: Virtual Reality Therapy
Torbay and South Devon NHS Foundation Trust, Torbay Hospital
Musculoskeletal
07/25
07/25

Download Options